Prelude Therapeutics

Update in progress

PRLD (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Prelude Therapeutics is a clinical-stage precision oncology company that develops novel cancer medicines for underserved patients. Its programs include JAK2V617F inhibitors for myeloproliferative neoplasms such as myelofibrosis, polycythemia vera, and essential thrombocythemia; KAT6A inhibitors for advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates for MF and ET. It collaborates with AbCellera. Founded in 2016, it is based in Wilmington, Delaware.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.20; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive